Ceramide 1-Phosphate Protects Endothelial Colony–Forming Cells From Apoptosis and Increases Vasculogenesis In Vitro and In Vivo
Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Virginie Mignon, Fernanda Parborell, Mirta Schattner, Catherine Boisson-Vidal, Soledad Negrotto

To cite this version:
Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Virginie Mignon, Fernanda Parborell, et al.. Ceramide 1-Phosphate Protects Endothelial Colony–Forming Cells From Apoptosis and Increases Vasculogenesis In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association, 2019, 39 (10), 10.1161/ATVBAHA.119.312766 . hal-02326078

HAL Id: hal-02326078
https://hal.archives-ouvertes.fr/hal-02326078
Submitted on 25 Oct 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Ceramide 1-Phosphate Protects Endothelial Colony–Forming Cells From Apoptosis and Increases Vasculogenesis In Vitro and In Vivo

Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Virginie Mignon, Fernanda Parborell, Mirta Schattner, Catherine Boisson-Vidal, Soledad Negrotto

OBJECTIVE: Ceramide 1-phosphate (C1P) is a bioactive sphingolipid highly augmented in damaged tissues. Because of its abilities to stimulate migration of murine bone marrow–derived progenitor cells, it has been suggested that C1P might be involved in tissue regeneration. In the present study, we aimed to investigate whether C1P regulates survival and angiogenic activity of human progenitor cells with great therapeutic potential in regenerative medicine such as endothelial colony-forming cells (ECFCs).

APPROACH AND RESULTS: C1P protected ECFC from TNFα (tumor necrosis factor-α)-induced and monosodium urate crystal–induced death and acted as a potent chemoattractant factor through the activation of ERK1/2 (extracellular signal-regulated kinases 1 and 2) and AKT pathways. C1P treatment enhanced ECFC adhesion to collagen type I, an effect that was prevented by β1 integrin blockade, and to mature endothelial cells, which was mediated by the E-selectin/CD44 axis. ECFC proliferation and cord-like structure formation were also increased by C1P, as well as vascularization of gel plug implants loaded or not with ECFC. In a murine model of hindlimb ischemia, local administration of C1P alone promoted blood perfusion and reduced necrosis in the ischemic muscle. Additionally, the beneficial effects of ECFC infusion after ischemia were amplified by C1P pretreatment, resulting in a further and significant enhancement of leg reperfusion and muscle repair.

CONCLUSIONS: Our findings suggest that C1P may have therapeutic relevance in ischemic disorders, improving tissue repair by itself, or priming ECFC angiogenic responses such as chemotaxis, adhesion, proliferation, and tubule formation, which result in a better outcome of ECFC-based therapy (Visual Overview).

Key Words: cell transplantation ■ endothelial progenitor cells ■ humans ■ ischemia ■ regeneration

Building new vascular networks to reestablish blood perfusion is one of the therapeutic goals to treat ischemic vascular diseases such as critical limb ischemia, stroke, and myocardial infarction. Restitution of blood flow to the injured site may require angiogenic sprouting of endothelial cells from nearby intact blood vessels, as well as the recruitment of endothelial progenitor cells from the bone marrow to initiate vasculogenesis. Several progenitor cell populations with a role in angiogenesis have been isolated; however, the endothelial colony–forming cells (ECFCs) truly represent an endothelial cell type with potent intrinsic clonal proliferative potential and capacity to contribute to de novo blood vessel formation in vivo. Moreover, ECFCs are the most potent vascular reparative cell type among endothelial progenitor cell candidates, and its key role on postischemia tissue vascularization has been shown in different models in athymic nude mice.

Sphingolipids are membrane lipids that have been considered for many years as simple structural cell components. However, in the last decades, increasing evidence has shown that sphingolipids are powerful bioactive...
Nonstandard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>bFGF</td>
<td>basic fibroblast growth factor</td>
</tr>
<tr>
<td>C1P</td>
<td>ceramide 1-phosphate</td>
</tr>
<tr>
<td>CERK</td>
<td>ceramide kinase</td>
</tr>
<tr>
<td>ECFC</td>
<td>endothelial colony–forming cell</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>extracellular signal-regulated kinases 1 and 2</td>
</tr>
<tr>
<td>HUVEC</td>
<td>human umbilical vein endothelial cell</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>intercellular adhesion molecule 1</td>
</tr>
<tr>
<td>IL</td>
<td>interleukin</td>
</tr>
<tr>
<td>MSU</td>
<td>monosodium urate crystals</td>
</tr>
<tr>
<td>PI3K</td>
<td>phosphatidylinositol 3-kinase pathway</td>
</tr>
<tr>
<td>SDF-1</td>
<td>stromal cell-derived factor 1</td>
</tr>
<tr>
<td>TGFβ1</td>
<td>transforming growth factor-β1</td>
</tr>
<tr>
<td>TNFα</td>
<td>tumor necrosis factor-α</td>
</tr>
<tr>
<td>VEGF</td>
<td>vascular endothelial growth factor</td>
</tr>
<tr>
<td>VEGFR2</td>
<td>vascular endothelial growth factor receptor 2</td>
</tr>
</tbody>
</table>

molecules, which regulate vital cellular functions such as the cell cycle and survival, as well as the inflammatory and immune responses. Ceramide—the fundamental structural unit of all sphingolipids—can be deacylated to sphingosine, which is then phosphorylated by sphingosine kinases (SPHK1 or SPHK2) to yield sphingosine 1-phosphate. Also, ceramide 1-phosphate (C1P) can be generated by phosphorylation of ceramide (N-acyl sphingosine) by CERK (ceramide kinase). Both sphingosine 1-phosphate and C1P production are increased under inflammatory conditions. While sphingosine 1-phosphate can be secreted by normal activated cells, C1P is released as a consequence of the loss of membrane permeability or cell rupture. Thus, C1P is considered a damage-associated molecular pattern as it rapidly and exponentially increases its levels in sites of tissue injury. C1P exerted antiapoptotic effects in several cell types, and it is a powerful chemoattractant not only for macrophages but also for different progenitor/stem cells, including murine bone marrow–derived endothelial progenitor cells. Moreover, C1P stimulates human umbilical vein endothelial cell (HUVEC)–mediated capillary-like tubule formation in vitro and matrigel implant vascularization. Interestingly, it has been reported that dermal microendothelial cells from CERK-deficient mice show profound defects in in vitro angiogenesis assays.

Based on this background, in the present study, we aimed to investigate whether C1P regulates survival and vasculogenic activity of human progenitor cells with a high potential in regenerative medicine such as ECFC. We found that C1P increases ECFC survival and angiogenic responses including chemotaxis, adhesion, proliferation, and tubule formation. Additionally, in an in vivo model of hindlimb ischemia, C1P improved tissue regeneration by itself and acted as a primer of ECFC regenerative properties.

MATERIALS AND METHODS

The authors declare that all supporting data are available within the article and its online-only Data Supplement.

Lipid Preparation and Endothelial Cell Culture

C8-C1P d18:1/8:0 (C8-C1P) and C16-C1P d18:1/16:0 (C16-C1P) were treated with 0.1, 1, or 10 µmol/L C8-C1P, C16-C1P, or vehicle. Pharmacological inhibitors of ERK1/2 (extracellular signal-regulated kinases 1 and 2; U-0126, cat No. BML-EI-282; Enzo Life Sciences International, Inc, San Diego, CA) or AKT (LY-294002, cat No. 860532P, C16 cat No. 860533P; Avanti Polar Lipids, Inc, Alabaster, AL) were added to ECFC cultures 30 minutes before C1P.

Experimental Design

Endothelial cells in endothelial basal medium 2 (Lonza, Walkersville, MD) with 2% fetal bovine serum or endothelial growth medium 2 (Lonza) were treated with 0.1, 1, or 10 µmol/L C8-C1P, C16-C1P, or vehicle. Pharmacological inhibitors of ERK1/2 (extracellular signal-regulated kinases 1 and 2; U-0126, cat No. BML-EI-282; Enzo Life Sciences International, Inc, San Diego, CA) or AKT (LY-294002, cat No. BML-ST420; Enzo Life Sciences International, Inc) were added to ECFC cultures 30 minutes before C1P.

Highlights

• Ceramide 1-phosphate supported vasculogenesis by increasing endothelial colony forming cell (ECFC) survival and acting as a potent ECFC chemotactic factor alone or in synergy with SDF-1 (stromal cell-derived factor 1).
• Ceramide 1-phosphate enhanced ECFC angiogenic properties including adhesion, proliferation, and tubule formation in vitro and in vivo.
• In a murine model of hindlimb ischemia, ceramide 1-phosphate induces postischemia revascularization and tissue repair by itself and further improved ECFC regenerative potential.
• Ceramide 1-phosphate might be considered a new therapeutic tool in ischemic disorders itself or as an improver of the outcome of ECFC-based therapy.
Measurement of Cell Viability

ECFCs cultured in endothelial basal medium 2/2% fetal bovine serum were treated with the different stimuli, and cell viability was determined after 24 hours by nuclear morphology analysis. Briefly, adherent cells were harvested using 0.05% trypsin and pooled with spontaneously detached cells. Cells were then stained with 100 µg/mL ethidium bromide and acridine orange (Sigma, St. Louis, MA), mounted on slides and immediately analyzed by fluorescence microscopy. At least 300 cells per treatment were counted.

A similar procedure was used to measure caspase-3 activation by flow cytometry. Briefly, cells were fixed, permeabilized, and then stained with fluorescein isothiocyanate-conjugated monoclonal antibody against the active fragment of caspase-3 (cat No. 51-68654X; BD Biosciences, Bedford, MA) for 30 minutes. Acquisition and analysis were achieved by flow cytometry (FACScalibur; BD Biosciences, San Jose, CA) using FlowJo (Flexera, Itasca, IL).

Measurement of Angiogenic Responses

Chemotaxis driven by C1P or SDF-1 (stromal-derived factor 1) was examined using transwells with 8.0-µm pore polycarbonate membrane inserts. The number of migrated cells was determined by counting under a high-power microscope.

For cell adhesion assays, ECFCs were stained with carboxyfluorescein succinimidyl ester and adhesion onto recombinant bovine fibronectin, rat tail collagen type I or HUVEC untreated or activated with TNFa (tumor necrosis factor-alpha) was determined after 1 hour. Images were obtained with phase-contrast confocal fluorescence microscopy using a FV-1000 microscope (Olympus), and the number of adherent cells was determined by cell count in 5 random fields.

ECFC proliferation was determined by cell counting in a Neubauer chamber or by carboxyfluorescein succinimidyl ester staining and flow cytometry.

Tube formation on reduced growth factor basement membrane matrix (cat No. A1413202, Geltrex; Gibco, Grand Island, NY) was examined by transwell and the total number of branch points was quantified by analyzing images of the entire surface. Image analysis was performed with ImageJ.

Intracellular pathway phosphorylation levels were measured by flow cytometry using specific antibodies against phospho AKT (Ser 473) followed by an HRP-conjugated secondary antibody anti-phospho ERK1/2 (Tyr 204) and anti-phospho P65 (Ser 311) and confirmed by Western blot using primary antibodies anti-phospho ERK1/2 (Tyr 204) and anti-phospho AKT (Ser 473) followed by an HRP-conjugated secondary antibody.

Animal Experiments

All experiments involving animals were performed according to protocols approved by the Animal Care and Use Committee of the Paris Descartes University Institutional Committee on Animal Care and Use (APAFIS No. 7443-201 61 020 1540639 v2). Animal care was conform to French guidelines (Services Vétérinaires de la Santé et de la Production Animale, Paris, France). Animals were housed in a temperature- and light-controlled (12/12-hour light/dark cycle) facility with free access to water and M20 standard diet (Special Diets Services, Witham, England).

RESULTS

C1P Promotes ECFC Survival and Migration

In adherence to the guidelines as described in the ATVB Council Statement (ATVB 2018;38:292–303), we reported that only 8-week-old nonconsanguine male NMR-Foxn1nu/Foxn1nu were used to exclude any effects of female hormones, such as estrogen, in this study. After treatment, mice were housed in clean cages (Tecniplast 1284 L Eurostandard type II L polysulfone, 5 mice/cage) in a well-ventilated room and allowed unrestricted access to feeds and water.

For Geltrex plug assay, mice were injected subcutaneously with 200 µL of Geltrex alone, or with C8-C1P (1 µmol/L), ECFC alone (1.5x10⁴), or ECFC and C8-C1P. Mice were euthanized on day 10, and the Geltrex plugs were photographed, and the hemoglobin concentration was measured in the supernatants with Drabkin reagent (Sigma).

Murine model of hindlimb ischemia, mice underwent surgery to induce unilateral hindlimb ischemia by ligation of the right femoral artery as described previously. ECFCs (1x10⁴) untreated or treated with C8-C1P (1 µmol/L) were administered 5 hours after occlusion in the retro-orbital plexus. Saline solution was used as vehicle. Some animals received intramuscular injection of C8-C1P (1 µmol/L), the ischemic/normal limb blood flow ratio was determined on day 14 using the laser Doppler perfusion imaging system PeriScan Pim3 (Perimed, Crappone, France). Gastrocnemius muscles from both hindlimbs were fixed in 4% formaldehyde and embedded in paraffin and stained with hematoxylin and eosin and then digitized for quantified necrotic, ischemic, or preserved area in each muscle and reported as a percentage of the entire surface area of the section. Vessel density was evaluated in sections stained with primary rat anti-mouse CD31 monoclonal antibody (cat No. 550274; BD Biosciences) and high-definition microangiography E-Image (Trophy system) and was expressed as the percentage of pixels per image in the quantification area occupied by vessels (CD31⁺ area).

Statistical Analysis

Results are expressed as means±SEM. P<0.05 was considered statistically significant. The Shapiro-Wilk test was used to define state normality and equal variance. In case of sample normality and equal variances, parametric tests such as 1- and 2-way ANOVA followed by Fisher or Student t test were used. If normality assumption failed, nonparametric tests such as Kruskal-Wallis followed by Dunn or Mann-Whitney U test were performed. All the tests were used according to the experimental design and analyzed using the GraphPad software (PRISM, version 8.0; San Diego, CA).
We found that while C16-C1P failed to induce ECFC death in all concentrations tested (0.1–10 µmol/L), C8-C1P had a significant cytotoxic effect at 10 µmol/L (Figure 1A). C1P induced ECFC apoptosis since nuclear morphology was compatible with apoptosis (nuclear pyknosis), and caspase-3 was activated by 10 µmol/L C8-C1P (C=2.0±0.5, C1P=18.8±4.8% of positive cells by flow cytometry; P<0.05, n=4).

Numerous studies support the antiapoptotic effect of C1P in different cell types including macrophages, keratinocytes, cochlear hair cells, and retina photoreceptors.11–14 To mimic the different stress signals present at the inflammatory and ischemic microenvironment, we induced apoptosis and necrosis with 2 molecules highly elevated in these contexts like TNFα and monosodium urate crystals (MSUs) at the indicated concentrations. Cell death was analyzed by fluorescence microscopy after 24 h (n=5–10). C-D) Chemotaxis in response to C8- or C16-C1P alone or together with SDF-1 (stromal cell-derived factor 1) was determined using transwell inserts. The number of migrated cells was counted after 6 h (n=4–6). *P<0.05 vs untreated controls; &P<0.05 vs TNFα or MSU alone; #P<0.05 vs SDF-1 alone, 1-way ANOVA.

Figure 1. Ceramide 1-phosphate (C1P) promoted endothelial colony–forming cell (ECFC) survival and migration. A, ECFCs were treated with different concentrations of C8- or C16-C1P, and cell death was analyzed by fluorescence microscopy after 24 h (n=6–8). B, ECFCs were pretreated with C8- or C16-C1P for 30 min and then exposed to TNFα (tumor necrosis factor-α) and monosodium urate crystals (MSUs) at the indicated concentrations. Cell death was analyzed by fluorescence microscopy after 24 h (n=5–10). C-D) Chemotaxis in response to C8- or C16-C1P alone or together with SDF-1 (stromal cell-derived factor 1) was determined using transwell inserts. The number of migrated cells was counted after 6 h (n=4–6). *P<0.05 vs untreated controls; &P<0.05 vs TNFα or MSU alone; #P<0.05 vs SDF-1 alone, 1-way ANOVA.

C1P Enhances Other ECFC Responses Involved in Vasculogenesis

Based on the therapeutic potential of ECFC in regenerative medicine, we next studied the effect of C1P in other responses, beyond chemotaxis, involved in vasculogenesis and tissue repair. To study ECFC adhesion, cells were placed onto a matrix protein-covered surface or cocultured with endothelial cells for 1 hour in the presence or absence of C1P. Adhesion to collagen type I, but not fibronectin, significantly was augmented by 1 µmol/L C8- or 10 µmol/L C16-C1P (Figure 2A). Moreover, adhesion bone marrow–residing progenitor cells like mesenchymal stem cells, small embryonic–like cells, and endothelial progenitor cells.10 We here demonstrated that both short and long versions of this sphingolipid stimulated human ECFC migration. C1P not only increased per se the number of migrated ECFCs in a concentration-dependent manner (Figure 1C) but also potentiated chemotaxis driven by SDF-1—the most powerful chemoattractant factor for undifferentiated cells (Figure 1D).
Figure 2. Ceramide 1-phosphate (C1P) enhanced endothelial colony–forming cell (ECFC) adhesion to collagen type I and endothelial cells.

A and B, ECFCs were treated with C8- or C16-C1P and seeded onto collagen type I, fibronectin, untreated or TNFα (tumor necrosis factor-α)-activated human umbilical vein endothelial cell (HUVEC) for 1 h. The number of adherent cells was counted (n=4–7). C–F, ECFCs were treated with C8-C1P in the presence or absence of 2.5 mg/mL blocking antibodies against β1 integrin (αβ1), E-selectin (αCD62E), CD44 (αCD44), ICAM-1 (intercellular adhesion molecule 1; αCD54), or αIgG and seeded onto collagen type I or untreated HUVEC for 1 h. The number of adherent cells was counted (n=3–6). *P<0.05 vs untreated controls; #P<0.05 vs C8-C1P alone, 1-way ANOVA or Kruskal-Wallis.
Figure 3. Ceramide 1-phosphate (C1P) increased endothelial colony-forming cell (ECFC) proliferation and tubulogenesis.

A, ECFCs were cultured in endothelial basal medium 2 (EBM2)/2% fetal bovine serum (FBS) or endothelial growth medium 2 (EGM2) treated with C8- or C16-C1P at the indicated concentrations, and proliferation was analyzed by cell count in a Neubauer chamber after 24 and 48 h (n=4–5). The dashed line indicates the initial cell number seeded. B, ECFCs were cultured in EGM2 treated with C8-C1P in the presence or absence of 3 mg/mL blocking antibodies against VEGFR2 (vascular endothelial growth factor receptor 2) or αIgG, and (Continued)
to mature endothelial cells (HUVECs) was increased by these sphingolipids in a concentration-dependent manner, regardless of whether HUVECs were previously activated by TNF-α or not (Figure 2B).

To understand the mechanism mediating the strong proadhesive action of C1P, we analyzed the participation of cell adhesion molecules like β1 integrin, coreceptor of collagen type I, as well as the E-selectin (CD62E)/CD44 axis and ICAM-1 (intercellular adhesion molecule 1; CD54), possible mediators of ECFC-HUVEC interaction. Of note, the expression of these adhesion molecules was studied on each cell type before and after C1P treatment, and only ICAM-1 was increased, whereas the rest of them remained unchanged (Figure I in the online-only Data Supplement). The enhanced adhesion to collagen type I was completely inhibited after β1 integrin blockade, whereas IgG control showed no effect (Figure 2C). Moreover, C8-C1P—induced adhesion to HUVEC was fully reduced in the presence of neutralizing antibodies against E-selectin or CD44, but not ICAM-1, indicating that the receptor/counterreceptor E-selectin-CD44 binding is responsible for ECFC-HUVEC adhesion induced by C1P (Figure 2D through 2F).

Furthermore, E-selectin mediates the interaction between the 2 endothelial cell types after a 1-hour coculture without adding C1P or any activating factor. To investigate the kinetics of E-selectin expression in cocultures, we performed a time course assay in both ECFC and HUVEC grown alone or together. In ECFC, no significant changes were observed in E-selectin expression after 5 and 20 minutes of coculture, whereas a significant increment was detected after 60 and 240 minutes of coculture. Similar data trends were observed in HUVECs, although an earlier significant alteration tendency was detected in this cell type after 20 minutes of coculture. In both cases, C1P further increased this process at early stages (20 and 6 minutes of coculture) but failed to potentiate E-selectin expression after 240 minutes (Figure II in the online-only Data Supplement).

Regarding cell proliferation, when ECFCs were cultured in endothelial basal medium 2/2% fetal bovine serum, no cell growth was observed in any condition (with or without C1P) because the total cell number at 24 and 48 hours was similar to the amount initially seeded (~10 000 cells; Figure 3A). As expected, ECFC growth was triggered by endothelial growth medium 2—an effect that was potentiated by C8-C1P and C16-C1P (1 and 10 µmol/L, respectively; Figure 3A). While C8-C1P slightly but significantly increased the total cell number after 24 hours, both C8- and C16-C1P augmented proliferation after 48 hours (Figure 3A). Flow cytometry analysis of cell division by carboxyfluorescein succinimidyl ester tracking yielded similar results after 24 (untreated: 34±2, C8-C1P 0.1 µM: 29±1, C8-C1P 1 µM: 46±3%, C16-C1P 1 µM: 33±1, C8-C1P 10 µM: 35±1% of positive cells; *P<0.05 versus untreated) and 48 hours (untreated: 49±1, C8-C1P 0.1 µM: 49±3, C8-C1P 1 µM: 71±2%, C16-C1P 1 µM: 58±2, C8-C1P 10 µM: 66±3% of positive cells; #P<0.05 versus untreated). The mitogenic effect of C1P was completely suppressed in the presence of the neutralizing antibody against VEGFR2 (vascular endothelial growth factor receptor 2), suggesting that C1P-induced ECFC proliferation depends on VEGF (vascular endothelial growth factor)/VEGFR2 axis (Figure 3B). On the contrary, we observed that C8-C1P failed to modify the secretion of the proangiogenic factors VEGF and bFGF (basic fibroblast growth factor), as well as TGFβ1 (transforming growth factor-β1) and IL (interleukin)-4, whereas it significantly upregulated the release of the anti-inflammatory cytokine IL-10 and downregulated the release of the proinflammatory IL-8 (Figure III in the online-only Data Supplement).

The formation of cord-like structures in vitro was significantly increased by C1P, C8-C1P being more potent than C16-C1P (Figure 3C). This effect was also observed in vivo using Geltrex plug implants in nude mice loaded (or not) with human ECFC. As shown in Figure 3D, C8-C1P not only has a potent vasculogenic effect by itself but also potentiates plug vascularization mediated by human ECFC.

ERK1/2 and AKT Pathways Are Involved in the Proangiogenic Effects of C1P

To elucidate the mechanism involved in the proangiogenic effects of C8-C1P, we next studied some of the classical pathways involved in ECFC functions, which have been reported to be regulated by C1P in other cell types (eg, macrophages, cancer cells) such as ERK1/2, PI3K (phosphatidylinositol 3-kinase pathway)/AKT, P38, and NFκB. Flow cytometric analysis showed that C1P increased the percentage of positive cells for pERK1/2 and pAKT but not for P38 and the NFκB subunit p65 (Figure 4A). Activation of these pathways was confirmed by Western blot (Figure 4B). Furthermore, pERK1/2 and pAKT pathways are key mediators of C8-1P proangiogenic effects since the increase in proliferation and chemotaxis induced by C8-C1P was completely inhibited by the pharmacological inhibitors of ERK1/2 (U-0126) and AKT (LY-294002; Figure 4C).

Figure 3 Continued. proliferation was analyzed by cell count in a Neubauer chamber after 24 and 48 h (n=3–4). C, ECFCs were treated with C8- or C16-C1P at the indicated concentrations and then seeded on Geltrex matrix. The number of branch points per field was measured after 18 h. Images are representative of 6 different experiments. D, Geltrex plugs were loaded with C8-C1P, ECFC, or their combination and subcutaneously implanted in nude mice. After 10 d, implants were removed; the concentration of Hb (hemoglobin) was measured using the Drabkin reagent. Images are representative of 5 different experiments. *P<0.05 vs untreated controls; #P<0.05 vs same treatment in EBM2/2%FBS; &P<0.05 vs C8-C1P with IgG, 1-way or 2-way ANOVA, Fisher correction.
Figure 4. Intracellular pathways involved in ceramide 1-phosphate (C1P) proangiogenic effects.

**A**, Endothelial colony–forming cells (ECFCs) treated with C8-C1P for 10 min and the phosphorylation of ERK1/2 (extracellular signal-regulated kinases 1 and 2), AKT, P38, and P65 were measured by flow cytometry (n=3–5). **B**, ECFCs treated with C8-C1P for 10 min and the phosphorylation of ERK1/2 and AKT was detected by immunoblotting. Each membrane was reprobed with an antibody against actin to calculate the relative IOD (n=4). **C**, ECFCs were treated with C8-C1P in the presence or absence of pharmacological inhibitors of AKT (LY-294002, 2.5 µmol/L) and ERK1/2 (U-0126, 2.5 µmol/L). Proliferation and C8-C1P–driven chemotaxis were determined after 48 and 6 h, respectively (n=3). *P<0.05 vs untreated controls; #P<0.05 vs C8-C1P alone, Student t test or 1-way ANOVA, Fisher correction.
C1P Directly Promotes Tissue Revascularization Post-Ischemia and Enhances the Therapeutic Potential of ECFC

The effect of C1P on the ECFC therapeutic potential for tissue regeneration was studied in a murine model of hindlimb ischemia. As expected, the intravenous injection of untreated ECFC significantly augmented the ischemic-to-nonischemic leg blood flow ratio, relative to vehicle-treated mice (Figure 5). Intramuscular injections of C1P significantly enhanced the perfusion in the ischemic hindlimb in comparison with PBS and slightly increase the revascularization mediated by untreated ECFC alone (Figure 5). Interestingly, the best outcome was observed in animals that received both intravenous administration of C1P-pretreated ECFC together with intramuscular injection of C1P. This latter treatment resulted in further and significant improvement of leg reperfusion compared with each condition alone (Figure 5).

The histomorphometric analysis of the distal gastrocnemius muscles on day 14 was performed by dividing the digitized muscle sections into 3 areas: (1) preserved area: normal histology including homogeneous fibers and peripheral nuclei; (2) ischemic area: tissue in regeneration with cellular alterations and central nuclei; (3) necrotic area: muscle cell destruction, nonhomogeneous fibers, and multicellular infiltration (Figure 6A). Our results showed that animals receiving intramuscular injections of C1P alone significantly reduced necrosis in the ischemic muscle in comparison with PBS-treated mice (Figure 6A), while capillary density was slightly increased (Figure 6B). As expected, intravenous infusion of untreated ECFC improved tissue repair significantly, although the administration of both untreated ECFC together with intramuscular injection of C1P showed no differences with animals receiving ECFC alone (Figure 6A and 6B). Outstandingly, administration of C1P-pretreated ECFC together with intramuscular C1P reduced necrosis and inflammatory infiltrate, exhibiting a higher percentage of preserved area (Figure 6A). Furthermore, this combined treatment resulted in a further and significant enhancement of capillary density compared with all conditions (Figure 6B). Of note, there was no episode of death or defects in ambulation in any group.

Considering that monocytes and macrophages are involved in vasculogenesis and C1P potently induced their migration, we aimed to analyze whether these immune cells play a role in the ECFC/C1P regenerative effect. Few immune cells were observed after 7 and 14 days post-surgery, showing no variances between the different experimental conditions (data not shown). An earlier analysis of muscle histology (day 4) showed that PBS-treated animals showed a considerable amount of macrophage infiltrating the ischemic muscles, which was higher when C1P alone was administered intramuscularly. However, animals receiving ECFC alone or in combination with C1P showed little macrophage infiltration (Figure IV in the online-only Data Supplement).

DISCUSSION

Therapeutic angiogenesis, and in particular, transplantation of adult bone marrow cells, including ECFC, has...
Figure 6. Administration of ceramide 1-phosphate (C1P)–pretreated endothelial colony–forming cell (ECFC) together with local C1P reduces necrosis and increased vascular density in the ischemic muscle.

A. Histological analysis of gastrocnemius muscles, stained with hematoxylin and eosin, was performed at day 14. Representative images of preserved, ischemic, and necrotic areas in the gastrocnemius muscle post-ischemia are shown. Original magnification, ×40. Scale bar=200 µm. The surface of each area type is reported as a percentage of the entire histological section surface. Black arrows indicate CD31+ vessels. Original magnification, ×40. Scale bar=200 µm (n=4–9). *P<0.05 vs PBS; #P<0.05 vs C1P-pretreated ECFC+C1P (intramuscularly [IM]); &P<0.05 vs all the treatments, 1-way ANOVA.

B. Vessel density was calculated as the percentage of CD31+ vessels in the total surface. Representative images of immunohistochemistry are shown. Black arrows indicate CD31+ vessels. Original magnification, ×40. Scale bar=200 µm (n=4–9). *P<0.05 vs PBS; #P<0.05 vs C1P-pretreated ECFC+C1P (intramuscularly [IM]); &P<0.05 vs all the treatments, 1-way ANOVA.
demonstrated exciting results and constitutes a promising approach for the treatment of ischemia. ECFC recruitment at the site of injury is a key step for tissue revascularization/repair, as well as their engraftment, which largely depends on the survival of the newly arrived cells within the hostile inflammatory microenvironment. In this sense, 2 of the best-known properties of C1P are chemotactic effect and cytoprotection. Numerous studies support the antiapoptotic effect of C1P in different cell types. In macrophages and keratinocytes, higher levels of endogenous C1P (after CERK activity upregulation) blocked apoptosis, whereas the exogenous addition of C1P to cohlear hair cell and retina photoreceptor cultures also increases cell survival. In line with this evidence, we here demonstrated that C1P protects ECFC not only from apoptosis but also from necrosis triggered by 2 molecules highly elevated in the ischemic tissue like TNFα and monosodium urate crystal, respectively..

We have used 2 analogs of C1P, a long-chain analog (C16-C1P), which is a major type of C1P in cells, considered like the natural C1P; and a short chain one (C8-C1P), because of its higher solubility in water and cellular permeability than the long-chain C1P. In fact, Gangoiti et al previously showed that optimal DNA synthesis was attained at lower concentrations when using C8-C1P than when using C16-C1P to stimulate cells. It is worth to mention that C8-C1P was not found in biological systems; therefore, their effects should be observed, as others suggested, as only pharmacological. Regarding cytoprotection, we found that C8-C1P exerted it maximal protective effect at 1 µmol/L and higher concentrations induced ECFC apoptosis, whereas C16-C1P failed to induce ECFC death in all concentrations tested (0.1–10 µmol/L) and effectively reduced cell death at 10 µmol/L. Both C1P analogs showed similar effects on ECFC functions when used at the maximum noncytotoxic concentrations.

As mentioned above, C1P is a well-known chemoattractant factor of monocytes, macrophages, pancreatic cancer cells, mesenchymal stem cells, endothelial cells, and several murine precursors, including bone marrow–derived endothelial progenitor cells. Our data showed that C1P acted as a potent chemoattractant factor for human ECFC and additionally potentiates the chemotactic effect of SDF-1—the major ECFC physiological chemotactic factor. Because it has been shown that C1P levels are upregulated in damaged tissues like carotid injury, irradiation, ischemic myocardium, our findings suggest that C1P, like SDF-1, can create a gradient to attract ECFC to the injury site. The angiogenic process involves ECFC homing and adhesion to activated endothelium or matrix proteins and their extravasation to target sites. In vivo, endothelial progenitor cells usually home to areas of altered shear stress, where the endothelial monolayer is activated and possibly denuded, exposing extracellular matrix proteins to the vascular lumen. These areas are believed to influence the adhesion and extravasation of progenitor cells to ischemic sites. Our results provide strong evidence that C1P stimulation enhances these events by promoting ECFC adhesion to collagen type I and mature endothelial cells (HUVEC). In this regard, β1 integrin seems to be responsible for C1P-induced ECFC adhesion to collagen as the effect was completely suppressed after its blockade. In addition, a complete inhibition of C1P-triggered adhesion to HUVEC was observed in the presence of neutralizing antibodies against E-selectin or CD44, but not ICAM-1, indicating that the E-selectin/CD44 axis is responsible for ECFC-HUVEC adhesion induced by C1P. Moreover, we observed that E-selectin also mediates the interaction between the 2 endothelial cell types after a 1-hour coculture without adding any activating factor, reinforcing the idea that coculturing itself promotes E-selectin expression and further suggesting that C1P–independent endothelial cell interaction is also mediated by E-selectin and CD44. These results raised the question: is it possible that E-selectin is significantly expressed on endothelial surface after 1-hour stimulation with C1P? Our results indicated that indeed, E-selectin is rapidly induced on each cell type when cultured together in the presence of C1P—a phenomenon that it is not observed when ECFC and HUVEC are grown separately. To the best of our knowledge, we here report that E-selectin is significantly expressed on ECFC surface as early as 60 minutes after coculture with HUVEC. Similar data were observed in HUVEC, although an earlier significant alteration tendency was detected in these cells, after 20 minutes of coculture. A fast expression of E-selectin on HUVEC has been reported before when cultured together with smooth muscle cells, after 15-minute stimulation with nicotine or 30-minute post-Flavivirus infection. Moreover, E-selectin expression was observed as early as 30 minutes after lipopolysaccharide administration in an in vivo model of cutaneous inflammation. The mechanisms of C1P-mediated E-selectin upregulation have not been investigated here. However, considering that the sole interaction between cells triggers E-selectin expression and C1P effect is only observed when cells are cultured together, it is conceivable that C1P acts as an enhancer of the cross talk between them.

It has been previously reported that C1P increased HUVEC adhesion to plastic, although the mechanisms involved were not identified. Additionally, C1P increased the expression of ICAM-1 on ECFC surface, although its blockade has no effect on ECFC-HUVEC interaction. Considering that C1P participates and regulates the inflammatory response, it is conceivable that ICAM-1 mediates ECFC contact with leukocytes—a fundamental step to allow the migration of these cells to the site of injury. Moreover, our results showing that C1P failed to modify the secretion of proangiogenic factors (VEGF, bFGF, etc) while significantly upregulated the release of
the anti-inflammatory cytokine IL-10 and downregulated the release of the proinflammatory IL-8 strengthen the idea that C1P regulates ECFC inflammatory responses. Similarly, it has been previously reported that C1P suppresses the release of proinflammatory cytokine from macrophages.38–40 How C1P regulates inflammation and the consequences for tissue repair is an interesting area of future investigation.

Other ECFC responses involved in vasculogenesis were also augmented by C1P. Although C1P had no effect itself on cell proliferation, both C8-C1P and C16-C1P induced ECFC expansion in the presence of a moderate amount of growth factors (1:2 dilution endothelial growth medium 2), suggesting a collaborative effect between them and C1P. In addition, this mitogenic action of C1P was completely suppressed by VEGFR2 blockade. In line with our finding, the involvement of VEGF/VEGFR2 axis on C1P-induced proliferation has been reported in RAW264.7 macrophages.41 C8-C1P augmented ECFC proliferation over time, whereas C16-C1P only showed significant differences after 48 hours. A similar C8-C1P–mediated mitogenic effect was previously observed in macrophages15 and aortic vascular smooth cells20 but not in C16-C1P–stimulated MSCs and mature endothelial cells (HUVEC, HREC, and HCAEC).9,10,29 The lack of effect of C16-C1P was probably because proliferation was analyzed after 24-hour stimulation—a time point in which we also failed to detect any effects. We also demonstrated that C1P promoted the formation of capillary-like network mediated by ECFC in vitro and the vasculogenesis in vivo in a murine model of subcutaneous capillary-like network mediated by ECFC in vitro and the also demonstrated that C1P promoted the formation of capillary-like network mediated by ECFC in vitro and the vasculogenesis in vivo in a murine model of subcutaneous capillary-like network mediated by ECFC in vitro and the angiogenic potency of the C1P-stimulated ECFC is likely to be attributable to both the beneficial effects of C1P on the proangiogenic potential of transplanted ECFC and the influence of C1P and ECFC on the ischemic hindlimb. In line with our evidence, it has been demonstrated that the priming of MSC with C1P improved the regenerative effect of these cells in a pulmonary artery hypertension rat model.26 Considering that C1P is a well-known chemoattractant factor for monocytes and macrophages, we would expect a higher number of monocytes/macrophages present within the ischemic muscles of animals treated with C1P alone and in combination with ECFC. While this is true for C1P alone, few inflammatory infiltrates were observed in ECFC-treated animals. Although these findings suggest that the number of macrophages/monocytes within the damaged area is not crucial for ECFC/C1P–mediated tissue repair, we cannot rule out that these immune cells still participate in this process at different time points or under other experimental conditions. In addition, the type of monocytes and macrophages migrating from peripheral blood or their polarization into inflammatory or anti-inflammatory phenotype among the different treatments should be considered as well. These issues are currently under investigation in our laboratory.

In conclusion, our finding suggests that C1P may be considered a new therapeutic tool in ischemic disorders, promoting tissue repair by itself or as a primer of ECFC survival and angiogenic responses, which result in a better outcome of ECFC-based therapy.

ARTICLE INFORMATION
Received March 18, 2019; accepted August 8, 2019.

Affiliations
From the Experimental Thrombosis Laboratory, Institute of Experimental Medicine, National Academy of Medicine—CONICET, Buenos Aires, Argentina (H.A.M.,
Mena et al

Ceramide 1-Phosphate Increases Vasculogenesis

PRZ, M.S.; SN3; Innovative Therapies in Haemostasis, INSERM (BD, CB-V) and INSERM US025, CNRS URMS 3612, PTICM (VM), Université de Paris, France; and Experimental Medicine and Biology Institute, CONICET, Buenos Aires, Argentina (FP).

Acknowledgments

We thank I. Dubail, V. Bertrand, Caroline Kharchi, and all the technicians from the animal facilities (UMS 3612 CNRS–URMS 3612, Parc Descartes University); A. Lokajczyk (INSERM U1140) for help concerning endothelial colony–forming cell cultures and experiments; and J. Rogozarski for her help in immunohistochemistry assays. We also thank the maternity services of Hospital Rivadavia (Buenos Aires) for providing umbilical cord and cord blood samples.

Sources of Funding

This study was financially supported by ANPCyT grants (PICT 1859/15 and 0612/13). Salary of C. Boisson-Vidal is paid by French CNRS.

Disclosures

None.

REFERENCES

22. Chu JJ, Chen LI, Lee CI, Lee PL, Dey TY, Tsai MC, Lin CW, Ussani S, Chen S. Ceramide 1-phosphate induces endothelial cell E-selectin expression by smooth

Arterioscler Thromb Vasc Biol. 2019;39:00–00. DOI: 10.1161/ATVBIAHA.119.312766

October 2019

13